Hims & Hers Health

Hims & Hers Health

Andrew Dudum launched Hims & Hers in 2017, building on his background in consumer brands like Atomic. The company was founded alongside Jack Abraham and Hilary Coles, initially focusing on a telehealth model for stigmatized conditions such as erectile dysfunction and hair loss. The core insight was that many consumers avoid in-person doctor visits for conditions they consider embarrassing, creating a market for discreet, online-first care. The company expanded rapidly into women's health with the Hers brand, and later into mental health and primary care, building a broad digital health platform with a direct-to-consumer model and a distinct, millennial-focused brand voice. It went public via a SPAC merger in January 2021. The company's strategy hinges on vertical integration across the healthcare value chain. Hims & Hers operates an owned pharmacy fulfillment network, including a facility in Ohio, which gives it control over compounding and distribution of its core products. It manages an in-house electronic medical record system and employs a network of licensed clinicians across all 50 states. The platform deploys AI for clinical decision support within its EMR and patient-facing diagnostic tools. Key product lines include compounded semaglutide for weight loss, which became a major growth driver beginning in 2023, as well as proprietary formulations for hair growth, sexual wellness, and dermatology. It sells these directly through its website and app, using a subscription model that generates recurring revenue from repeat prescriptions. Customer acquisition leans heavily on performance marketing across social media and podcasts, which as of 2024 accounted for the majority of its quarterly marketing spend. The firm reported revenue of $1.24 billion in 2024, alongside its first full year of GAAP profitability. The subscriber base surpassed 1.8 million by early 2025. Hims & Hers competes directly with established telehealth platforms like Teladoc and Ro, as well as traditional pharmacy chains that have launched their own digital offerings. Its weight-loss program in particular emerged as a significant revenue engine, driven by consumer demand for GLP-1 alternatives during supply shortages of brand-name drugs. The company has expanded the scope of services within its platform, adding lab tests, at-home diagnostic kits, and long-term care management tools. The firm's structural differentiator lies in treating healthcare as a consumer brand problem rather than a clinical infrastructure play — a posture that shapes its marketing tactics, product design, and even its regulatory risk profile. Hims & Hers is a publicly traded company, not a private asset manager, so analysis from an allocator's perspective centers on its role as a disruptor in the healthcare sector and its influence on direct-to-consumer care models. The company has faced scrutiny from the FDA regarding its compounding practices and marketing claims for certain products, a dynamic that shapes ongoing operational and reputational calculus.